This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Diabetic retinopathy remains a major cause of vision loss among working-age individuals worldwide. While chronic hyperglycemia is a well-known risk factor, the study sheds light on the role of acute ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...

Diabetic retinopathy happens when elevated blood sugar levels cause damage to the blood vessels in the retina. The retina plays a crucial role in transmitting visual images to the brain.